PRESS RELEASE
EQL Pharma AB (publ)
Org.no. 556713-3425

2018-03-05

Hydroxyzine EQL Pharma

In March 2017, the European Medicines Agency EMA recommended a temporary withdrawal of several drugs for which bioequivalence studies were conducted at Micro Therapeutic Research Labs. Among these were the drug Hydroxyzine EQL Pharma.

A new bioequivalence study has now been completed and approved by the authorities. This means that EQL Pharma, once again, can start selling its hydroxyzine products on both the Swedish and Danish market.

"The authorities' approval is expected, but still good news. Our portfolio's still small and therefore the company is sensitive to disturbances in individual products, "says Christer Fåhraeus, CEO of EQL Pharma.

For further information, please contact:
Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

About EQL Pharma

EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets nine (9) niche generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (8) people and is listed on AktieTorget. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.